1.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: DFCI-04006, AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: EGF102988, NCT00424255
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CASE-3307-CC389, CASE-3307, CASE-CC389, CASE3307-CC389, NCT00608205
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 0120070101, NCT00705068
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Hx-EGFr-203, NCT00401401
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: UCIRB #14735B, GV-001.010 (TNF-ELF), NCT00496236
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: UCIRB #14733B, GV-001.011 (TNF-CORE), NCT00496535
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 07-069, NCT00570674
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: X90003, NCT00660218
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-15461, IND 102483, LBH589, NCT00738751
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: J08101, CA180123, NCT00882583
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: DFCI-03018, NCT00095927
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 12652A, NCT00203905
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OSU-0482, NCT00293579
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: OSI-3601S, Genentech, Inc., NCT00304278
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: H-26154 (GCC 0442), CA225092, NCT00343083
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06U.195, NCT00358007
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-111, NCT00392665
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MSKCC-06130, PFIZER-MSKCC-06130, NCT00423930
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UWCC-6106, 6106, UWCC-05-9278-H/B, GENENTECH-OSI3602s, FHCRC-6106, NCT00410826
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-283, NCT00459043
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO 06-1155, NCT00462735
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 14401A, NCT00468169
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ENT0020, 97864, ENT0020, LAP #109855, NCT00490061, NCT00490061
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2006-0940, NCT00494182
|